GlassScriptPhysician profile
Lorraine Innes
NPI 1194769976
$9,128.21
in general payments reported to CMS, 2019-2025
30 companies · $1,925 in 2025
The $1,925 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,449 · 2020: $1,324 · 2021: $1,355 · 2022: $885 · 2023: $1,092 · 2024: $1,099 · 2025: $1,925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,115.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,178.23 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,137.74 | 2020-2025 | Caplyta |
| Abbvie INC. | $1,137.10 | 2021-2025 | |
| Lundbeck LLC | $865.77 | 2019-2025 | Rexulti |
| Allergan, INC. | $741.58 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $731.07 | 2019-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $522.32 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $520.75 | 2022-2025 | Lybalvi, Aristada |
| Bausch Health US, LLC | $343.57 | 2019-2025 | Aplenzin |
| Otsuka America Pharmaceutical, INC. | $296.16 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Tris Pharma INC | $214.11 | 2024-2025 | Dyanavel Xr, Onyda Xr |
| Axsome Therapeutics, INC. | $207.64 | 2024-2025 | Auvelity |
| Arbor Pharmaceuticals, INC. | $158.06 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $143.83 | 2019-2022 | |
| Adlon Therapeutics L.P. | $126.64 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $117.10 | 2020-2023 | Belsomra |
| Corium, LLC | $114.69 | 2023-2025 | Azstarys |
| Eisai INC. | $100.55 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $78.36 | 2023-2025 | Qelbree, Qelbree |
| Alfasigma USA, INC. | $74.34 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $63.01 | 2020-2024 | |
| E.R. Squibb & Sons, L.L.C. | $48.39 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $42.14 | 2022-2024 | Austedo Xr |
| Vanda Pharmaceuticals INC. | $37.12 | 2025 | Fanapt |
| Almatica Pharma LLC | $31.32 | 2025 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $30.22 | 2023-2024 | Quviviq |
| Vertical Pharmaceuticals, LLC | $23.24 | 2024 | Relexxii |
| Collegium Pharmaceutical, INC. | $17.61 | 2025 | Jornay Pm |
| Shire North American Group INC | $13.93 | 2019 | |
| Currax Pharmaceuticals LLC | $11.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorraine Innes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.